BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) Fundamental Analysis & Valuation

AMS:BACE • KYG137071075

10 USD

+0.1 (+1.01%)

Last: Mar 14, 2023, 07:00 PM

This BACE.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1. BACE.AS Profitability Analysis

1.1 Basic Checks

BACE had positive earnings in the past year.

1.2 Ratios

		Industry Rank	Sector Rank
ROA	0.5%
ROE	24.82%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BACE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA ROE ROIC Operating and Profit Margin Show most profitable peers

2. BACE.AS Health Analysis

2.1 Basic Checks

2.2 Solvency

An Altman-Z score of 1.89 indicates that BACE is not a great score, but indicates only limited risk for bankruptcy at the moment.
BACE has a Debt/Equity ratio of 47.13. This is a high value indicating a heavy dependency on external financing.

		Industry Rank	Sector Rank
Debt/Equity	47.13
Debt/FCF	N/A
Altman-Z	1.89

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 35.22 indicates that BACE has no problem at all paying its short term obligations.
A Quick Ratio of 35.22 indicates that BACE has no problem at all paying its short term obligations.

		Industry Rank	Sector Rank
Current Ratio	35.22
Quick Ratio	35.22

More info and screens

WACC Debt/Equity How to determine the health of a company Altman-Z score Show peers with great health

3. BACE.AS Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks Show best growing peers

4. BACE.AS Valuation Analysis

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 55.56, which means the current valuation is very expensive for BACE.
Compared to an average S&P500 Price/Earnings ratio of 25.71, BACE is valued quite expensively.

		Industry Rank	Sector Rank
PE	55.56
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Price/Earnings Price/FCF FCF per share EV/EBITDA PEG RATIO Show best valued peers

5. BACE.AS Dividend Analysis

5.1 Amount

BACE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks Show peers with best dividend

BACE.AS Fundamentals: All Metrics, Ratios and Statistics

BRIGADE-M3 EUROPEAN ACQUIS-A

AMS:BACE (3/14/2023, 7:00:00 PM)

+0.1 (+1.01%)

Chartmill FA Rating

GICS SectorN/A

GICS IndustryGroupN/A

GICS IndustryN/A

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap287.50M

Revenue(TTM)N/A

Net Income(TTM)1.28M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	55.56
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	60.07
P/tB	60.07
EV/EBITDA	N/A

EPS(TTM)0.18

EY1.8%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS0.17

TBVpS0.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	0.5%
ROE	24.82%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	47.13
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	35.22
Quick Ratio	35.22
Altman-Z	1.89

F-Score1

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1YN/A

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

BRIGADE-M3 EUROPEAN ACQUIS-A / BACE.AS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BACE.AS.

Can you provide the valuation status for BRIGADE-M3 EUROPEAN ACQUIS-A?

ChartMill assigns a valuation rating of 0 / 10 to BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS). This can be considered as Overvalued.

Can you provide the profitability details for BRIGADE-M3 EUROPEAN ACQUIS-A?

BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) has a profitability rating of 0 / 10.

Can you provide the PE and PB ratios for BACE stock?

The Price/Earnings (PE) ratio for BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) is 55.56 and the Price/Book (PB) ratio is 60.07.